Table of Contents

company-logo

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Contineum Therapeutics Dividend Announcement

• Contineum Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Contineum Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Contineum Therapeutics Dividend History

Contineum Therapeutics Dividend Yield

Contineum Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Contineum Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Contineum Therapeutics Financial Ratios

P/E ratio-14.03
PEG ratio-0.14
P/B ratio2.37
ROE-49.92%
Payout ratio0.00%
Current ratio37.06
Quick ratio37.06
Cash Ratio7.04

Contineum Therapeutics Dividend FAQ

Does Contineum Therapeutics stock pay dividends?
Contineum Therapeutics does not currently pay dividends to its shareholders.
Has Contineum Therapeutics ever paid a dividend?
No, Contineum Therapeutics has no a history of paying dividends to its shareholders. Contineum Therapeutics is not known for its dividend payments.
Why doesn't Contineum Therapeutics pay dividends?
There are several potential reasons why Contineum Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Contineum Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Contineum Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Contineum Therapeutics a dividend aristocrat?
Contineum Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Contineum Therapeutics a dividend king?
Contineum Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Contineum Therapeutics a dividend stock?
No, Contineum Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Contineum Therapeutics stocks?
To buy Contineum Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Contineum Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.